MHRA authorises plozasiran (Redemplo) for adults with familial chylomicronaemia syndrome
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 19 October 2026, authorised plozasiran (Redemplo)
Résiliable à tout moment · 99 $ CA/mois


